Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00791479 · ClinicalTrials.gov registry record · Phase 2
Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 167
- Enrollment target
NCT00791479 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 167 participants.
The verdict
NCT00791479, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 167 participants
- Enrollment target
Study Summary
This is a study to demonstrate that different doses of once-weekly LY2189265 injected subcutaneously will have dose proportional effect on hemoglobin A1c (HbA1c) at 12 weeks in participants with type 2 diabetes mellitus.
Interventions
- DRUG LY2189265 and Lifestyle Measures
- DRUG Placebo solution and Lifestyle Measures
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00791479
The ClinicalTrials.gov registry entry for NCT00791479 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LY2189265 and Lifestyle Measures is the first listed.
NCT00791479 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00791479 about?
NCT00791479 is a clinical study titled "Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes". This is a study to demonstrate that different doses of once-weekly LY2189265 injected subcutaneously will have dose proportional effect on hemoglobin A1c (HbA1c) at 12 weeks in participants with type 2 diabetes mellitus.
What is the current status of trial NCT00791479?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 167 participants. The study started on 2008-12. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00791479?
The interventions under investigation include: LY2189265 and Lifestyle Measures (DRUG), Placebo solution and Lifestyle Measures (DRUG).
Who is sponsoring clinical trial NCT00791479?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.